Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818102 | 1.00 | MEN1 (0.64) | MEN1KMT2ANPC1L3MBTL1NPSR1 | |
| SCHEMBL14030202 | 0.86 | L3MBTL1 (0.64) | MEN1KMT2ANPC1L3MBTL1NPSR1 | |
| SCHEMBL13702277 | 0.86 | L3MBTL1 (0.64) | KMT2ANPC1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL29818228 | 0.85 | LMNA (0.62) | NPC1L3MBTL1ALDH1A1TSHRHPGD | |
| SCHEMBL7082686 | 0.84 | TSHR (0.73) | MEN1KMT2ANPC1NPSR1ALDH1A1 | |
| SCHEMBL3647370 | 0.84 | ALDH1A1 (0.64) | NPC1L3MBTL1NPSR1ALDH1A1USP2 | |
| SCHEMBL13947589 | 0.84 | LMNA (0.78) | NPC1L3MBTL1NPSR1ALDH1A1USP2 | |
| SCHEMBL29437184 | 0.84 | NPC1 (0.61) | NPC1L3MBTL1NPSR1ALDH1A1USP2 | |
| SCHEMBL11626565 | 0.84 | NPC1 (0.81) | MEN1KMT2ANPC1L3MBTL1NPSR1 | |
| SCHEMBL11628250 | 0.84 | NPSR1 (0.67) | KMT2ANPC1L3MBTL1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3787612-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112312899-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| EP-1763509-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ANO1, ANO2, CACYBP | MEN1 1152/4885KMT2A 4212/4885NPC1 2582/4885 |
| US-20080153802-A1 | Alpha-helical mimetics | BID, BAX, BAD | MEN1 2219/4885KMT2A 2959/4885NPC1 3792/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | MEN1 1108/4885KMT2A 1185/4885NPC1 1448/4885 |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, CD47, GLI1 | MEN1 279/4885KMT2A 450/4885NPC1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.